GSK agreed to license Hutchmed’s KRAS-EGFR antibody-targeted therapy conjugate HMPL-A830, paying $110 million upfront with total deal value up to $1.295 billion plus royalties. The asset is preclinical and is designed to deliver a KRAS inhibitor payload selectively to EGFR-expressing tumors while simultaneously blocking EGFR and KRAS signaling. The transaction reinforces GSK’s oncology strategy to expand into antibody-drug conjugate-adjacent mechanisms and multi-target pathway disruption. It also signals continued confidence that pairing tumor-targeting antibodies with KRAS inhibition can improve therapeutic index for difficult-to-treat cancers. For partners and competitors, the key watch item will be whether Hutchmed’s conjugate can translate preclinical dual-mode action into measurable clinical responses as KRAS-targeting approaches face persistent efficacy and safety hurdles.